CVRx's Q1 revenue rises 20%, beats expectations

CVRx

11/05/2026 21:13

Overview

Medical device maker's Q1 revenue rose 20% yr/yr, beating analyst expectations

U.S. revenue up 22%, driven by expansion and Barostim awareness

Net loss narrowed to $13.1 mln, or $0.50 per share

Outlook

CVRx expects Q2 2026 revenue between $15.1 mln and $16.1 mln

Company maintains full-year 2026 revenue guidance of $63.0 mln to $67.0 mln

CVRx updates full-year gross margin guidance to 85%-87%, up from 84%-86%

Result Drivers

U.S. EXPANSION - Revenue growth driven by expansion into new sales territories and new accounts in the U.S. heart failure business

BAROSTIM AWARENESS - Increased physician and patient awareness of Barostim contributed to higher U.S. revenue

Company press release: ID:nGNX3kR3yq

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$14.77 mln
$14.48 mln (7 Analysts)
Q1 EPS
-$0.50
Q1 Net Income
-$13.12 mln
Q1 Basic EPS
-$0.50
Q1 Gross Profit
$12.88 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for CVRx Inc is $12.00, about 75.7% above its May 8 closing price of $6.83

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)